UROGEN PHARMA ($URGN) posted quarterly earnings results for Q4 2025 on Monday, March 2nd. The company reported earnings of -$0.54 per share, missing estimates of -$0.51 by $0.03. The company also reported revenue of $37,840,000, missing estimates of $40,720,827 by $-2,880,827.
You can see Quiver Quantitative's $URGN stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
UROGEN PHARMA Insider Trading Activity
UROGEN PHARMA insiders have traded $URGN stock on the open market 10 times in the past 6 months. Of those trades, 0 have been purchases and 10 have been sales.
Here’s a breakdown of recent trading of $URGN stock by insiders over the last 6 months:
- MARK SCHOENBERG (Chief Medical Officer) has made 0 purchases and 5 sales selling 18,244 shares for an estimated $411,819.
- JASON DREW SMITH (General Counsel) has made 0 purchases and 4 sales selling 8,999 shares for an estimated $176,308.
- CHRIS DEGNAN (Chief Financial Officer) sold 2,203 shares for an estimated $37,120
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
UROGEN PHARMA Hedge Fund Activity
We have seen 82 institutional investors add shares of UROGEN PHARMA stock to their portfolio, and 95 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TORONTO DOMINION BANK removed 3,190,510 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $74,721,744
- AMERICAN CENTURY COMPANIES INC added 1,358,812 shares (+inf%) to their portfolio in Q4 2025, for an estimated $31,823,377
- HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND added 1,125,100 shares (+inf%) to their portfolio in Q4 2025, for an estimated $26,349,842
- MILLENNIUM MANAGEMENT LLC removed 849,785 shares (-57.9%) from their portfolio in Q4 2025, for an estimated $19,901,964
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 830,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $16,558,500
- MPM BIOIMPACT LLC added 806,378 shares (+597.3%) to their portfolio in Q4 2025, for an estimated $18,885,372
- FRONTIER CAPITAL MANAGEMENT CO LLC added 781,620 shares (+inf%) to their portfolio in Q4 2025, for an estimated $18,305,540
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
UROGEN PHARMA Government Contracts
We have seen $240,780 of award payments to $URGN over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- JELMYTO KIT - ANTINEOPLASTIC ANTIBIOTICS: $204,528
- ZUSDURI MEDICATION: $32,844
- JELMYTO KITS: $3,408
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
UROGEN PHARMA Analyst Ratings
Wall Street analysts have issued reports on $URGN in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- D. Boral Capital issued a "Buy" rating on 10/27/2025
- HC Wainwright & Co. issued a "Buy" rating on 10/27/2025
To track analyst ratings and price targets for UROGEN PHARMA, check out Quiver Quantitative's $URGN forecast page.
UROGEN PHARMA Price Targets
Multiple analysts have issued price targets for $URGN recently. We have seen 2 analysts offer price targets for $URGN in the last 6 months, with a median target of $36.5.
Here are some recent targets:
- Jason Kolbert from D. Boral Capital set a target price of $33.0 on 01/23/2026
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $40.0 on 10/27/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
